Weight-loss jab could be made for $3 a month, study finds

The WHO designated semaglutide – sold to treat obesity under the Wegovy brand name and diabetes under the brand name Ozempic – as an essential medicine last year. Photograph: Getty

Weight-loss jabs such as Wegovy could be made for just $3 a month, according to new analysis, potentially making the treatment available to millions in poorer countries as patents expire.

More than a billion people live with obesity worldwide, with rates rising fast in lower-income nations as they shift to westernised diets and more sedentary lifestyles.